二级市场

Reliance Industries’ digital services arm Jio Platforms saw its qualified institutional buyers’ (QIBs) portion fully subscribed within minutes of opening…

Founders, stop worshipping your pitch deck: IPO markets buy proof, reputation and belief, not your script.

Update | October 19, 2026 20:35 IST B2B manufacturing company Zetwerk’s ₹5,012.3 Cr IPO was oversubscribed 3.06X at the end…

Defence tech company Tonbo Imaging’s IPO has been oversubscribed 40.82X on the third day of bidding till now. Till 13:23…

Inside UC’s ₹2,500 Cr Fundraise Plan A year after listing, Urban Company is back in the market for more funds.…

It’s already called the biggest IPO in India, but Reliance Industries Limited is leaving no stone unturned. RIL chairman Mukesh…

Hunger Pangs, the parent of restaurant chain Burma Burma, has filed its DRHP for an IPO comprising a fresh issue…

Markets regulator SEBI has given its go-ahead to gym chain Cult.fit’s ₹950 Cr IPO about three months after it filed…

Defence tech company Tonbo Imaging’s ₹852.1 Cr IPO continued to receive healthy investor interest on the second day of bidding.…

B2B manufacturing company Zetwerk’s ₹5,012.3 Cr IPO was subscribed 27% on the second day of bidding today. Investors placed bids…

From the Iran war to rising geopolitical tensions across the globe, conflicts are driving demand for advanced defence technologies, from…

从国内清退的老头乐，在美国半年赚了5个亿。

Shopify’s India Checkout Bet Shopify is preparing to bring Shop Pay to India. Setting up a direct clash with domestic…

The Securities and Exchange Board of India (SEBI) has proposed sweeping changes to the rules governing initial public offerings (IPOs)…

B2B manufacturing company Zetwerk’s ₹5,012.3 Cr IPO got off to a rather slow start today, receiving a mere 8% subscription…

Defence tech startup Tonbo Imaging’s IPO was fully subscribed within hours of opening for bidding, with demand led by non-institutional…

Jio All Set For Its Mega IPO Reliance’s digital crown is heading down the Dalal Street. In what could be…

Iambic Therapeutics（前身为 Entos）是一家人工智能医疗平台开发商，从事人工智能制药，跨多个目标类别和作用机制，快速向诊所提供治疗药物。公司于10月15日在纳斯达克全球精选市场挂牌交易，股票代码为“IAM”。摩根大通、杰富瑞、美国银行证券和花旗集团担任联席簿记管理人。每股16美元，发行937.5万股，预计募资1.5亿美元，承销商另获30天内额外购买最多140.625万股的选择权。